Cargando…

Probiotics and atherosclerosis – a new challenge?

BACKGROUND: Atherosclerosis is the major cause of cardiovascular disease and stroke, which are among the top 10 leading causes of death worldwide. Pathogen-associated molecular patterns (PAMPs) can activate toll-like receptors (TLRs) and activate nuclear factor kappa B (NFκB) signaling, a central pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Kwan, Chan Yee, Kirjavainen, Pirkka, Yan, Chen, El-Nezami, Hani
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Co-Action Publishing 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3744656/
http://dx.doi.org/10.3402/mehd.v23i0.18576
_version_ 1782280621342588928
author Kwan, Chan Yee
Kirjavainen, Pirkka
Yan, Chen
El-Nezami, Hani
author_facet Kwan, Chan Yee
Kirjavainen, Pirkka
Yan, Chen
El-Nezami, Hani
author_sort Kwan, Chan Yee
collection PubMed
description BACKGROUND: Atherosclerosis is the major cause of cardiovascular disease and stroke, which are among the top 10 leading causes of death worldwide. Pathogen-associated molecular patterns (PAMPs) can activate toll-like receptors (TLRs) and activate nuclear factor kappa B (NFκB) signaling, a central pathway in inflammation, which regulates genes that encode proinflammatory molecules essential in atherogenesis. Lipopolysaccharides (LPS), which is unique to gram negative bacteria, as well as peptidoglycan (PGN), which is found in gram positive bacteria are PAMPS and ligands of TLR4 and TLR2, respectively, both of which are essential in plaque progression in atherosclerosis. Gastrointestinal tract is suggested to be the major site for absorption and translocation of TLR2 and TLR4 stimulants. Inflammation can result in a ‘leaky gut’ that leads to higher bacterial translocation, eventually the accumulation of LPS and PGN would activate TLRs and trigger inflammation through NFκB and promote further systemic complication like atherosclerosis. Probiotics, can protect the intestinal barrier to reduce bacterial translocation and have potential systemic anti-inflammatory properties. OBJECTIVE: To evaluate whether probiotics can help reduce atherosclerotic development using in vivo study. DESIGN: Apolipoprotein E knockout (ApoE(−/ −)) mice were fed on high fat diet alone, with telmisartan (Tel) (1 or 5 mg/kg/day, positive controls) or with probiotics (VSL#3/LGG) with or without Tel (1 mg/kg/day) for 12 weeks. RESULTS: Probiotics, Tel, or a combination of both reduced lesion size at the aortic root significantly; VSL#3 reduced serum inflammatory adhesion molecules soluble E- (sE-)selectin, soluble intercellular adhesion molecule 1 (sICAM-1), soluble vascular cell adhesion molecule 1 (sVCAM-1), and plaque disrupting factor matrix metalloproteinase (MMP)-9 significantly; probiotics and Tel at 5 mg/kg/day could induce changes in gut microbiota population; the efficiency of lesion reduction seemed to correlate to the microbiota composition; probiotics seemed to reduce plasma endotoxin but did not reach statistical significance. CONCLUSION: Probiotics has the potential to be used as a cheap, non-invasive, and with little side effects way to reduce atherosclerosis that brings worldwide benefits.
format Online
Article
Text
id pubmed-3744656
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Co-Action Publishing
record_format MEDLINE/PubMed
spelling pubmed-37446562013-08-29 Probiotics and atherosclerosis – a new challenge? Kwan, Chan Yee Kirjavainen, Pirkka Yan, Chen El-Nezami, Hani Microb Ecol Health Dis Supplement 2, 2012 BACKGROUND: Atherosclerosis is the major cause of cardiovascular disease and stroke, which are among the top 10 leading causes of death worldwide. Pathogen-associated molecular patterns (PAMPs) can activate toll-like receptors (TLRs) and activate nuclear factor kappa B (NFκB) signaling, a central pathway in inflammation, which regulates genes that encode proinflammatory molecules essential in atherogenesis. Lipopolysaccharides (LPS), which is unique to gram negative bacteria, as well as peptidoglycan (PGN), which is found in gram positive bacteria are PAMPS and ligands of TLR4 and TLR2, respectively, both of which are essential in plaque progression in atherosclerosis. Gastrointestinal tract is suggested to be the major site for absorption and translocation of TLR2 and TLR4 stimulants. Inflammation can result in a ‘leaky gut’ that leads to higher bacterial translocation, eventually the accumulation of LPS and PGN would activate TLRs and trigger inflammation through NFκB and promote further systemic complication like atherosclerosis. Probiotics, can protect the intestinal barrier to reduce bacterial translocation and have potential systemic anti-inflammatory properties. OBJECTIVE: To evaluate whether probiotics can help reduce atherosclerotic development using in vivo study. DESIGN: Apolipoprotein E knockout (ApoE(−/ −)) mice were fed on high fat diet alone, with telmisartan (Tel) (1 or 5 mg/kg/day, positive controls) or with probiotics (VSL#3/LGG) with or without Tel (1 mg/kg/day) for 12 weeks. RESULTS: Probiotics, Tel, or a combination of both reduced lesion size at the aortic root significantly; VSL#3 reduced serum inflammatory adhesion molecules soluble E- (sE-)selectin, soluble intercellular adhesion molecule 1 (sICAM-1), soluble vascular cell adhesion molecule 1 (sVCAM-1), and plaque disrupting factor matrix metalloproteinase (MMP)-9 significantly; probiotics and Tel at 5 mg/kg/day could induce changes in gut microbiota population; the efficiency of lesion reduction seemed to correlate to the microbiota composition; probiotics seemed to reduce plasma endotoxin but did not reach statistical significance. CONCLUSION: Probiotics has the potential to be used as a cheap, non-invasive, and with little side effects way to reduce atherosclerosis that brings worldwide benefits. Co-Action Publishing 2012-06-18 /pmc/articles/PMC3744656/ http://dx.doi.org/10.3402/mehd.v23i0.18576 Text en © 2012 FFF Probiotics 2012 - Abstracts http://creativecommons.org/licenses/by/2.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Supplement 2, 2012
Kwan, Chan Yee
Kirjavainen, Pirkka
Yan, Chen
El-Nezami, Hani
Probiotics and atherosclerosis – a new challenge?
title Probiotics and atherosclerosis – a new challenge?
title_full Probiotics and atherosclerosis – a new challenge?
title_fullStr Probiotics and atherosclerosis – a new challenge?
title_full_unstemmed Probiotics and atherosclerosis – a new challenge?
title_short Probiotics and atherosclerosis – a new challenge?
title_sort probiotics and atherosclerosis – a new challenge?
topic Supplement 2, 2012
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3744656/
http://dx.doi.org/10.3402/mehd.v23i0.18576
work_keys_str_mv AT kwanchanyee probioticsandatherosclerosisanewchallenge
AT kirjavainenpirkka probioticsandatherosclerosisanewchallenge
AT yanchen probioticsandatherosclerosisanewchallenge
AT elnezamihani probioticsandatherosclerosisanewchallenge